While the reiteration of an Outperform rating by Oppenheimer indicates continued confidence in DiaMedica Therapeutics, the reduction in the price target from $7 to $6 suggests a slight adjustment in expectations. This could be due to a variety of factors such as market conditions, recent company performance, or updated financial analysis. The impact on the stock price is likely neutral in the short term as the positive sentiment from maintaining an Outperform rating may balance out the negative sentiment from lowering the price target.